SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

Balance Sheet

Inspect the capital base behind the business.

Assets

$78.34M

FY 2025 · Annual

+303.2% YoY

Liabilities

$7.47M

FY 2025 · Annual

-25.0% YoY

Equity

$70.87M

FY 2025 · Annual

+648.8% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.46M17.13M2.53M13.89M71.89M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets27K330K100K100K223K
Total Current Assets23.04M17.76M3.17M16.33M75.21M
Property, Plant & Equipment (Net)723K874K858K925K963K
Goodwill1.91M1.91M1.91M1.91M1.91M
Intangible Assets00000
Long-term Investments0(184K)000
Tax Assets152K184K000
Other Non-current Assets594K399K275K466K257K
Total Non-current Assets3.38M3.19M3.05M3.31M3.13M
Total Assets26.43M20.94M6.22M19.43M78.35M
Account Payables2.14M3.36M5.64M3.5M2.95M
Short-term Debt198K000544K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.65M5.5M1.54M1.82M1.77M
Total Current Liabilities4.98M15.52M13.74M9.51M7.02M
Long-term Debt00000
Deferred Tax Liabilities152K184K000
Deferred Revenue (Non-current)0(184K)000
Other Non-current Liabilities336K4K000
Total Non-current Liabilities1.1M577K460K457K457K
Total Liabilities6.08M16.09M14.2M9.97M7.47M
Common Stock2K2K3K7K15K
Retained Earnings(138.6M)(179.9M)(217.24M)(248.13M)(274.99M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.35M4.85M(7.98M)9.47M70.87M
Total Debt808K945K906K1M1M
Net Debt(20.65M)(16.18M)(1.62M)(12.89M)(70.89M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$134.7M
Other Current$3.9M
Total Current Assets$138.6M
PP&E (Net)$578.0K
Goodwill$1.9M
Other Non-current$25.0K
Total Non-current Assets$2.5M
Total Assets$141.1M

Analysis

Selected assets total $141.1M for Latest. The largest visible component is Cash & Equivalents at $134.7M, about 95.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
10-QQuarterly reportAug 11, 2026

How much cash does SLS have?

SELLAS Life Sciences Group, Inc. (SLS) reported $71.89M in cash and equivalents in fiscal 2025.

How much debt does SLS carry?

SELLAS Life Sciences Group, Inc. (SLS) reported $1.00M of total debt, with net debt of -$70.89M.